{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:41:53Z","timestamp":1771069313888,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T00:00:00Z","timestamp":1267660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Neurocysticercosis (NC) is one of the most frequent parasitic diseases of the central nervous system. Cysticidal drugs, albendazole and praziquantel, are generally effective when parasites localize in the parenchyma. In contrast, parasites lodged in the subarachnoid basal cisterns are less responsive to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>The clinical and radiological pictures of six Mexican patients non-respondent to cysticidal treatment are presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The possible factors involved in the cysticidal non-response are discussed and hints are provided of potentially useful changes to therapeutic protocols.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2377-10-16","type":"journal-article","created":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T19:15:12Z","timestamp":1267730112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series"],"prefix":"10.1186","volume":"10","author":[{"given":"Graciela","family":"C\u00e1rdenas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Carrillo-Mezo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edda","family":"Sciutto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis Soto","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,4]]},"reference":[{"key":"297_CR1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s00415-004-0437-9","volume":"251","author":"A Fleury","year":"2004","unstructured":"Fleury A, Dessein A, Preux PM, Dumas M, Tapia G, Larralde C, Sciutto E: Symptomatic human neurocysticercosis--age, sex and exposure factors relating with disease heterogeneity. J Neurol. 2004, 251: 830-837. 10.1007\/s00415-004-0437-9.","journal-title":"J Neurol"},{"key":"297_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2174\/156802608783790811","volume":"8","author":"H Jung","year":"2008","unstructured":"Jung H, C\u00e1rdenas G, Sciutto E, Fleury A: Medical treatment for neurocysticercosis: drugs, indications and perspectives. Curr Trop Med Chem. 2008, 8: 424-433. 10.2174\/156802608783790811.","journal-title":"Curr Trop Med Chem"},{"key":"297_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.7326\/0003-4819-145-1-200607040-00009","volume":"145","author":"OH Del Brutto","year":"2006","unstructured":"Del Brutto OH, Roos KL, Coffey CS, Garc\u00eda HH: Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. 2006, 145: 43-51.","journal-title":"Ann Intern Med"},{"key":"297_CR4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/jnnp.2008.144899","volume":"79","author":"A Carpio","year":"2008","unstructured":"Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H, Hauser WA, Ecuadorian Neurocysticercosis Group: Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2008, 79: 1050-1055. 10.1136\/jnnp.2008.144899.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"297_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp.62.6.659","volume":"62","author":"OH Del Brutto","year":"1997","unstructured":"Del Brutto OH: Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. J Neurol Neurosurg Psychiatry. 1997, 62: 659-661. 10.1136\/jnnp.62.6.659.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"297_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/clind\/15.5.799","volume":"15","author":"JC Bandres","year":"1992","unstructured":"Bandres JC, White AC, Samo T, Murphy EC, Harris RL: Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin Infect Dis. 1992, 15: 799-811.","journal-title":"Clin Infect Dis"},{"key":"297_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1056\/NEJMoa010212","volume":"345","author":"JV Proa\u00f1o","year":"2001","unstructured":"Proa\u00f1o JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I: Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. 2001, 345: 879-885. 10.1056\/NEJMoa010212.","journal-title":"N Engl J Med"},{"key":"297_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/01.wnl.0000195887.63124.dc","volume":"66","author":"F G\u00f6ngora-Rivera","year":"2006","unstructured":"G\u00f6ngora-Rivera F, Soto-Hern\u00e1ndez JL, Gonz\u00e1lez Esquivel D, Cook HJ, M\u00e1rquez-Caraveo C, Hern\u00e1ndez D\u00e1vila R, Santos-Zambrano J: Albendazole trial at 15 or 30 mg\/kg\/day for subarachnoid and intraventricular cisticercosis. Neurology. 2006, 66: 436-438. 10.1212\/01.wnl.0000195887.63124.dc.","journal-title":"Neurology"},{"key":"297_CR9","first-page":"58","volume":"148","author":"L Cohen","year":"1992","unstructured":"Cohen L, Belec L, Sanson M, Pierrot-Deseilligny C, Signoret JL: Selective sensitivity of cysts to praziquantel and albendazole in a case of cerebral cysticercosis. Rev Neurol. 1992, 148: 58-61.","journal-title":"Rev Neurol"},{"key":"297_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/pgmj.67.788.577","volume":"67","author":"MS Chong","year":"1991","unstructured":"Chong MS, Hawkins CP, Cook GC, Hawkes CH, Kocen RS: A resistant case of neurocysticercosis. Postgrad Med J. 1991, 67: 577-578. 10.1136\/pgmj.67.788.577.","journal-title":"Postgrad Med J"},{"key":"297_CR11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.33588\/rn.4611.2007640","volume":"46","author":"JA Diazgranados-Sanchez","year":"2008","unstructured":"Diazgranados-Sanchez JA, Barrios-Arr\u00e1zola G, Costal JL, Burbano-Pabon J, Pinz\u00f3n-Bedova J: Ivermectin aas therapeuthic alternative in neurocysticercosis that is resistant to conventional pharmacological treatment. Rev Neurol. 2008, 46: 671-674.","journal-title":"Rev Neurol"},{"key":"297_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1590\/S0004-282X2008000100032","volume":"66","author":"MA Rocha Jr","year":"2008","unstructured":"Rocha MA, Santos JM, Gomes EC, Rocha MA, Rocha CF, Carvalho GT, Costa BS: Treatment of cerebral cysticercosis with albendazole in elevated dosages. Arq Neuropsiquiatr. 2008, 66: 114-116.","journal-title":"Arq Neuropsiquiatr"},{"key":"297_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11250-006-4346-z","volume":"38","author":"MM Sissay","year":"2006","unstructured":"Sissay MM, Asefa A, Uggla A, Waller PJ: Assessment of anthelmintic resistance in nematode parasites of sheep and goats owned by smallholder farmers in eastern Ethiopia. Trop Anim Health Prod. 2006, 38: 215-222. 10.1007\/s11250-006-4346-z.","journal-title":"Trop Anim Health Prod"},{"key":"297_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s11250-009-9311-1","volume":"41","author":"T Equale","year":"2009","unstructured":"Equale T, Chaka H, Gizaw D: Efficacy of albendazole against nematode parasites isolated from a goat farm in Ethiopia: Relationship between dose and efficacy in goats. Trop Anim Health Prod. 2009, 41: 1267-1273. 10.1007\/s11250-009-9311-1.","journal-title":"Trop Anim Health Prod"},{"key":"297_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00436-009-1363-7","volume":"105","author":"E Jimenez-Cardoso","year":"2009","unstructured":"Jimenez-Cardoso E, Eligio-Garcia L, Cortes-Campos A, Flores-Luna A, Valencia-Mayoral P, Lozada-Chavez I: Changes in beta-giardin sequence of Gardia intestinalis sensitive and resistant to albendazole strains. Parasitol Res. 2009, 105: 25-33. 10.1007\/s00436-009-1363-7.","journal-title":"Parasitol Res"},{"key":"297_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/157341307780619224","volume":"3","author":"PK Mittapalli","year":"2007","unstructured":"Mittapalli PK, Yamasani MR, Shashank A: Improved Bioavailability of Albendazole Following Oral Administration of Nanosuspension in Rats. Current Nanoscience. 2007, 3: 191-194. 10.2174\/157341307780619224.","journal-title":"Current Nanoscience"},{"key":"297_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/jac\/dkl463","volume":"59","author":"F Palomares Alonso","year":"2007","unstructured":"Palomares Alonso F, Piliado JC, Palencia G, Ortiz-Plata A, Jung-Cook H: Efficacy of nitazoxanide, tizoxanide and tizoxanide\/albendazole sulphoxide combinations against Taenia crassi ceps cysts. J Antimicrob Chemother. 2007, 59: 212-218. 10.1093\/jac\/dkl463.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-10-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-10-16\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-10-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-10-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T01:01:56Z","timestamp":1739926916000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-10-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,4]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-10-16","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,4]]},"assertion":[{"value":"8 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"16"}}